For research use only. Not for therapeutic Use.
RYL-552（Cat No.:I035845）is a selective inhibitor known for targeting the phosphoinositide 3-kinase gamma (PI3Kγ) pathway, an essential signaling component in immune cell function and inflammation. By modulating PI3Kγ, RYL-552 offers potential therapeutic applications in treating autoimmune diseases, inflammatory disorders, and certain cancers where PI3Kγ signaling is dysregulated. This specificity allows for reduced off-target effects, enhancing its safety profile. RYL-552 is instrumental in preclinical research focused on immune modulation, serving as a promising candidate in the development of therapies that require targeted immune response regulation.
| Catalog Number | I035845 |
| CAS Number | 1801444-56-3 |
| Synonyms | RYL-552 |
| Molecular Formula | C24H17F4NO2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | 5-fluoro-3-methyl-2-[4-[[4-(trifluoromethoxy)phenyl]methyl]phenyl]-1H-quinolin-4-one |
| InChI | InChI=1S/C24H17F4NO2/c1-14-22(29-20-4-2-3-19(25)21(20)23(14)30)17-9-5-15(6-10-17)13-16-7-11-18(12-8-16)31-24(26,27)28/h2-12H,13H2,1H3,(H,29,30) |
| InChIKey | OPUNZJHITPCTFC-UHFFFAOYSA-N |
| SMILES | CC1=C(NC2=C(C1=O)C(=CC=C2)F)C3=CC=C(C=C3)CC4=CC=C(C=C4)OC(F)(F)F |
| Reference | 1: Yang Y, Yu Y, Li X, Li J, Wu Y, Yu J, Ge J, Huang Z, Jiang L, Rao Y, Yang M. Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria. J Med Chem. 2017 Mar 9;60(5):1994-2005. doi: 10.1021/acs.jmedchem.6b01733. Epub 2017 Feb 22. PubMed PMID: 28195463. |
